Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Our lead product is ILUVIEN, now approved for marketing in the U...
TRICIDA
Post IPO Equity • South San Francisco, United States
Emmaus Medical
Post IPO Equity • Torrance, United States
Catalyst Pharmaceuticals
Post IPO Equity • Coral Gables, United States
Spectrum Pharmaceuticals
Post IPO Equity • Henderson, United States
DURECT
Post IPO Equity • Cupertino, United States
Insys Therapeutics
Post IPO Equity • Phoenix, United States
Zosano Pharma
Post IPO Debt • Fremont, United States
Regulus Therapeutics
Post IPO Equity • San Diego, United States
Trevena
Post IPO Equity • King of Prussia, United States
Senti Biosciences
Post IPO Equity • South San Francisco, United States
Fulcrum Therapeutics
Post IPO Equity • Cambridge, United States
VistaGen Therapeutics
Post IPO Equity • South San Francisco, United States